Syndax Pharmaceuticals, Inc. (SNDX)
20.70
-0.08
(-0.38%)
USD |
NASDAQ |
Sep 03, 10:42
Syndax Pharmaceuticals Research and Development Expense (TTM) : 261.79M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 261.79M |
| March 31, 2026 | 255.98M |
| December 31, 2025 | 258.78M |
| September 30, 2025 | 245.67M |
| June 30, 2025 | 260.36M |
| March 31, 2025 | 246.79M |
| December 31, 2024 | 241.64M |
| September 30, 2024 | 231.23M |
| June 30, 2024 | 199.35M |
| March 31, 2024 | 185.31M |
| December 31, 2023 | 162.76M |
| September 30, 2023 | 139.36M |
| June 30, 2023 | 127.07M |
| March 31, 2023 | 122.08M |
| December 31, 2022 | 118.04M |
| September 30, 2022 | 110.10M |
| June 30, 2022 | 108.80M |
| March 31, 2022 | 95.94M |
| December 31, 2021 | 87.79M |
| September 30, 2021 | 79.41M |
| Date | Value |
|---|---|
| June 30, 2021 | 68.30M |
| March 31, 2021 | 62.46M |
| December 31, 2020 | 50.24M |
| September 30, 2020 | 44.35M |
| June 30, 2020 | 39.88M |
| March 31, 2020 | 41.25M |
| December 31, 2019 | 42.99M |
| September 30, 2019 | 49.31M |
| June 30, 2019 | 53.48M |
| March 31, 2019 | 56.05M |
| December 31, 2018 | 60.11M |
| September 30, 2018 | 60.88M |
| June 30, 2018 | 58.98M |
| March 31, 2018 | 53.99M |
| December 31, 2017 | 48.20M |
| September 30, 2017 | 40.08M |
| June 30, 2017 | 40.16M |
| March 31, 2017 | 36.43M |
| December 31, 2016 | 31.66M |
| September 30, 2016 | 24.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viking Therapeutics, Inc. | 509.32M |
| Kura Oncology, Inc. | 259.47M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |